DM
About
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical’s shares are traded on Nasdaq Stockholm First North, ticker DMYD B.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 1,264 investors are based in Stockholm, Stockholms Lan, Sweden.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Stockholm, Sweden
Contact Information
Find more investors like Diamyd
Search Investors